January 18, 2022

CMS Decision on Alzheimer’s Drug Coverage

CMS Decision on Alzheimer’s Drug Coverage

About This Episode

The Centers for Medicare and Medicaid Services (CMS), the federal health insurance program for people 65 plus, announced its decision to deny covering Biogen’s Aduhelm and all future anti-amyloid treatments under what is known as a Coverage with Evidence Development (CED).  What does this first-round decision mean? 

BrainStorm host, Meryl Comer, and guest, Stephanie Monroe, Executive Director of AfricanAmericansAgainstAlzheimer's and Co-Director of the Center for Brain Health Equity discuss the underlying issues that she calls discriminatory, particularly for communities of color.  

Russ Paulsen, Chief Operating Officer at UsAgainstAlzheimer’s, offers a statement on why UsAgainstAlzheimer’s opposes the CMS decision and provides a statement explaining what this means for those living with Alzheimer’s. 

The proposed National Coverage Determination is open to public comment for 30 days (until Feb 9). A final decision will be announced in April. 

BrainStorm Feed

89

The Invisible Workforce: Why Caregiving is Both Personal and Economic Crisis with Paul Irving

In this episode of BrainStorm, Paul Irving discusses the PBS documentary produced by Bradley Cooper called Caregiving with host Meryl Comer.
LISTEN NOW
88

Breaking the Silence: Jay Reinstein’s Mission to End Alzheimer's Stigma

In this episode of BrainStorm, host Meryl Comer talks with Jay Reinstein, a former assistant city manager in North Carolina, about his 12 to15-month journey involving neuropsychological testing and brain scans before being diagnosed with early-onset Alzheimer's at age 57.
LISTEN NOW
87

Agitation and Alzheimer’s with Nancy Treaster

In this episode of BrainStorm Nancy Treaster, a certified caregiving advocate and co-host of The Caregiver's Journey podcast, shares her professional and personal experiences with

LISTEN NOW